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OBJECTIVE A systematic review was performed to provide objective evidence on the use of stereotactic radiosurgery
(SRS) in the management of secretory pituitary adenomas and develop consensus recommendations.
METHODS The authors performed a systematic review of the English-language literature up until June 2018 using the
PRISMA guidelines. The PubMed (Medline), Embase, and Cochrane databases were searched. A total of 45 articles
reporting single-institution outcomes of SRS for acromegaly, Cushing’s disease, and prolactinomas were selected and
included in the analysis.
RESULTS For acromegaly, random effects meta-analysis estimates for crude tumor control rate, crude endocrine
remission rate, and any new hypopituitarism rates were 97.0% (95% CI 96.0%–98.0%), 44.0% (95% CI 35.0%–53.0%),
and 17.0% (95% CI 13.0%–23.0%), respectively. For Cushing’s disease, random effects estimates for crude tumor control rate, crude endocrine remission rate, and any new hypopituitarism rate were 92.0% (95% CI 87.0%–95.0%), 48.0%
(95% CI 35.0%–61.0%), and 21.0% (95% CI 13.0%–31.0%), respectively. For prolactinomas, random effects estimates
for crude tumor control rate, crude endocrine remission rate, and any new hypopituitarism rate were 93.0% (95% CI
90.0%–95.0%), 28.0% (95% CI 19.0%–39.0%), and 12.0% (95% CI 6.0%–24.0%), respectively. Meta-regression analysis
did not show a statistically significant association between mean margin dose with crude endocrine remission rate or
mean margin dose with development of any new hypopituitarism rate for any of the secretory subtypes.
CONCLUSIONS SRS offers effective tumor control of hormone-producing pituitary adenomas in the majority of patients
but a lower rate of endocrine improvement or remission.
https://thejns.org/doi/abs/10.3171/2021.2.JNS204440

KEYWORDS acromegaly; Cushing’s disease; prolactinomas; secretory pituitary adenomas; pituitary surgery;
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ABBREVIATIONS ACTH = adrenocorticotrophic hormone; GH = growth hormone; IGF-1 = insulin-like growth factor–1; ISRS = International Stereotactic Radiosurgery
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SRS = stereotactic radiosurgery.
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ituitary adenomas (PAs) are common benign neoplastic lesions arising from cells of the anterior pituitary gland. Approximately 70% of PAs are associated with hormonal hypersecretion syndromes, among
which the most common are tumors secreting prolactin
(PRL), growth hormone (GH), or adrenocorticotrophic
hormone (ACTH).1 The management of secretory PA
represents a significant challenge because of the need to
adequately control hormonal hypersecretion in addition
to tumor growth. Management options for secretory PA
include medical therapy, surgical resection, and radiation therapy (RT), alone or in combination. Stereotactic
radiosurgery (SRS) is being increasingly used whenever
possible as an alternative to fractionated RT, with the goal
of limiting radiation exposure to adjacent normal tissues.
However, the literature regarding the use of SRS in the
treatment of PAs comprises only multiple retrospective
studies. This study was performed under the International
Stereotactic Radiosurgery Society (ISRS) guideline project to systematize the available literature and develop
consensus recommendations to guide the care of patients
afflicted by the most common secretory subtypes: prolactinomas, acromegaly (GH secreting), and Cushing’s
disease (ACTH secreting).

Methods

Selection of Articles
Using the PRISMA guidelines,2 a systematic review of
the English-language literature up until June 2018 was performed. The PubMed (Medline), Embase, and Cochrane
databases were searched for relevant articles using the
following MeSH terms: (Gamma Knife OR Radiosurgery
OR LINAC OR CyberKnife) AND (pituitary adenoma
OR Cushing’s disease OR acromegaly OR prolactinoma).
The initial search provided 1045 articles whose titles and
abstracts were screened for relevance, with 134 articles
retained at this stage. Full-text screening was performed
by using the following inclusion criteria: single-institution
study, more than 10 patients reported, and both tumor and
endocrine control data reported. Studies reporting the
use of proton-based SRS or fractionated stereotactic RT
and studies only reporting Nelson syndrome cases were
excluded. In cases where multiple studies were from the
same institution, only the most recent relevant publication
with the most extensive data was included. After full-text
screening, a total of 45 articles were selected for the final analyses. All studies were retrospective and reported
low-quality evidence. Many studies reported pooled outcomes of all PAs treated at the reporting institution. From
those, the data reporting the outcomes of Cushing’s disease, acromegaly, or prolactinoma were extracted, and the
data were extracted separately for those three different
subtypes. Separate analyses were performed for each secretory subtype. The final review included 28 acromegaly
studies, 13 Cushing’s disease studies, and 13 prolactinoma
studies. Figure 1 describes the search strategy and inclusion methodology as a PRISMA flow diagram.
Outcome Measures and Statistical Analyses
The primary outcomes of the study were endocrine re2

mission off medication and tumor control rates for each
of the 3 main secretory subtypes. Endocrine and cranial
nerve morbidity was also assessed. Data collection included the number of cases per study, radiosurgery device
used, mean follow-up time, prior resection, mean margin
radiation dose and dose range, mean tumor volume, local
control rate, endocrine remission and relapse rates, time
to remission, criteria used for endocrine remission definition, predictors of endocrine response, new or worsening
pituitary insufficiency rates, and new or worsening visual
or cranial nerve morbidity.
Statistical analyses were performed using R Studio
(version 1.1.423). Meta-analyses, tests for heterogeneity,
analysis of publication bias, and meta-regressions were
done with R package metafor (version 2.0-0). Study variances for the overall estimates and for meta-regression
were calculated using the DerSimonian-Laird method.
Weighted random effects models were used to calculate
pooled estimates for crude rates of local control, endocrine remission rate, and new-onset hypopituitarism for
each of the secretory subtypes. Given the study population
variances across the studies, and since each study involves
treatment decisions, the random effects model was considered superior to the fixed effects model when calculating
pooled estimates. The I2 statistic was used for identifying
heterogeneity: I2 values of 0%, 25%, 50%, and 75% were
interpreted as indicating absent, low, moderate, and high
heterogeneity, respectively. Funnel plots and the Egger
test (p value < 0.05 indicating presence of bias) were used
for identifying publication bias. Meta-regression analyses
were performed to identify potential associations between
endocrine remission rate or development of new-onset hypopituitarism and mean margin dose.

Results

Acromegaly
A total of 28 studies reporting acromegaly cases met
inclusion criteria and were evaluated in the final analysis
(Supplementary Table 1). All studies were retrospective
and provided low-quality evidence. Selected articles were
published between 1998 and 2018. The majority of studies
reported patients treated by Gamma Knife radiosurgery
(21 studies).3–23 CyberKnife was used in 2 studies,24,25
linear accelerator (LINAC)–based SRS in 4 studies,26–29
and a rotating gamma unit (MASEP) in 1 study.30 A total of 1335 patients were included in the meta-analysis.
SRS was usually performed for recurrence or adjuvant
treatment after tumor resection (65%–100% prior tumor
resection in all except 2 studies). In single-fraction studies, mean margin doses reported ranged from 13.2 to 35
Gy. Reported tumor control rates varied between 94%
and 100%, and new neurological or visual deficit rates
ranged between 0% and 11%. Crude endocrine remission
rates varied between 0% and 82%. However, there was
variability among studies relative to the criteria used to
define endocrine cure. Only one study used the current
consensus definition (GH level after an oral glucose tolerance test [OGTT] less than 0.4 ng/ml and normalization of age- and sex-adjusted insulin-like growth factor–1
[IGF-1] levels).31 The most common criteria to define re-
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FIG. 1. PRISMA flow diagram demonstrating the search strategy for study selection and inclusion in the systematic review for
secretory PA SRS. Figure is available in color online only.

mission were normalization of age- and sex-adjusted IGF1 levels and random GH values less than 2–2.5 ng/ml,
used in 10 studies (35.7%). New or worsened hypopituitarism was reported in 0%–40% of treated patients. The
following factors were identified by some studies as being
predictors of endocrine remission: GH and IGF-1 levels
less than 2.25 times normal at time of SRS, 5,8,14,17 absence
of cavernous sinus invasion,8,11 male sex,11 higher margin
dose,21 and absence of suppressive medication at SRS.14
Random effects meta-analyses for crude tumor control,
crude endocrine remission, and any new hypopituitarism
are shown in Figs. 2–4, with random effects estimates of
97.0% (95% CI 96.0%–98.0%), 44.0% (95% CI 35.0%–
53.0%), and 17.0% (95% CI 13.0%–23.0%), respectively.
Publication bias was assessed by using the Egger test. No
evidence of publication bias was found for the studies included for assessing crude tumor control rate (p = 0.251)
and crude endocrine remission rate (p = 0.782). However,
publication bias was evident for studies included for assessing new hypopituitarism rate (p = 0.039). Funnel plots
for publication bias are shown in Supplementary Fig. 1.
Supplementary Fig. 2 shows meta-regression plots for
association of mean margin dose with crude endocrine
remission rate and any new hypopituitarism rate. Metaregression analysis did not show a statistically significant

association between mean margin dose with crude endocrine remission rate (p = 0.054) and mean margin dose
with any new hypopituitarism rate (p = 0.685).
Cushing’s Disease
A total of 13 studies reporting Cushing’s disease cases
met inclusion criteria and were evaluated in the final analysis (Supplementary Table 2). All studies were retrospective and provided low-quality evidence. Selected articles
were published between 1998 and 2018. Eight studies reported patients treated by Gamma Knife radiosurgery,4,12,
20,32–36
whereas LINAC-based SRS was used in 4 studies29,37–39 and a rotating gamma unit (MASEP) in 1 study.30
A total of 416 patients were included in the meta-analysis.
SRS was usually performed for recurrence or adjuvant
treatment after tumor resection (57%–100% prior tumor
resection in all except 1 study). The mean margin dose
reported ranged from 14.7 to 35 Gy. Reported tumor control rates varied between 83% and 100%, and new neurological or visual deficit rates ranged between 0% and 17%.
Crude endocrine remission rates varied between 6% and
81%. There was variability among studies relative to the
criteria used to define endocrine cure, with the most common criteria used being normalization of 24-hour urinary
J Neurosurg September 3, 2021
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FIG. 2. Forest plot for crude tumor control rate for acromegaly. Squares indicate the proportions from individual studies and
horizontal lines indicate the 95% CI. The size of the data marker corresponds to the relative weight assigned in the pooled analysis
using the random effects model. The diamond indicates the pooled proportion with 95% CI.

free cortisol in 5 studies (38.5%). New or worsened hypopituitarism was reported in 0%–50% of treated patients.
The following factors were identified by some studies as
being predictors of endocrine remission: smaller target
volume,36 lower urinary cortisol level at SRS,33 and absence of suppressive medication at SRS.34,36
Random effects meta-analyses for crude tumor control,
crude endocrine remission, and any new hypopituitarism
are shown in Fig. 5, with random effects estimates of
92.0% (95% CI 87.0%–95.0%), 48.0% (95% CI 35.0%–
61.0%), and 21.0% (95% CI 13.0%–31.0%), respectively.
Publication bias was assessed by using the Egger test. No
evidence of publication bias was found for the studies included for assessing crude tumor control rate (p = 0.198)
and crude endocrine remission rate (p = 0.524). However,
publication bias was evident for studies included for assessing new hypopituitarism rate (p = 0.023). Funnel plots
for publication bias are shown in Supplementary Fig. 3.
Supplementary Fig. 4 shows meta-regression plots for
association of mean margin dose with crude endocrine
4

remission rate and any new hypopituitarism rate. Metaregression analysis did not show a statistically significant
association between mean margin dose with crude endocrine remission rate (p = 0.563) or mean margin dose with
any new hypopituitarism rate (p = 0.952).
Prolactinomas
A total of 13 studies reporting prolactinoma cases met
inclusion criteria and were evaluated in the final analysis
(Supplementary Table 3). All studies were retrospective
and provided low-quality evidence. Selected articles were
published between 1998 and 2018. Nine studies reported
patients treated by Gamma Knife radiosurgery,12,20,22,40–45
whereas LINAC-based SRS was used in 3 studies,29,46,47
and a rotating gamma unit (MASEP) in 1 study.30 A total
of 538 patients were included in the meta-analysis. SRS
was performed after prior tumor resection in 2%–100%
of cases for patients who had tumor growth and persistent hyperprolactinemia on medical therapy, or who were
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FIG. 3. Forest plot for crude endocrine remission rate for acromegaly. Squares indicate the proportions from individual studies and
horizontal lines indicate the 95% CI. The size of the data marker corresponds to the relative weight assigned in the pooled analysis
using the random effects model. The diamond indicates the pooled proportion with 95% CI.

intolerant to medication. The mean margin dose reported
ranged from 13.5 to 35 Gy. Reported tumor control rates
varied between 86% and 100%, and new neurological or
visual deficit rates ranged between 0% and 5%. Crude
endocrine remission rates varied between 6% and 81%.
There was variability among studies relative to the criteria
used to define endocrine cure, with most (8 studies, 61.5%)
only stating normal PRL levels without specifying any
numeral value or if patients needed to be off antisecretory medication. New or worsened hypopituitarism was
reported in 0%–62% of treated patients. The following
factors were identified by some studies as being predictors
of endocrine remission: tumor volume less than 3 ml,41
PRL levels less than 200 µg/L,41 and margin dose more
than 30 Gy.45 None of the included studies reported the use
of a dopamine agonist at SRS as a significant predictor of
endocrine outcome.
Random effects meta-analyses for crude tumor control,

crude endocrine remission, and any new hypopituitarism
are shown in Fig. 6, with random effects estimates of
93.0% (95% CI 90.0%–95.0%), 28.0% (95% CI 19.0%–
39.0%), and 12.0% (95% CI 6.0%–24.0%), respectively.
Publication bias was assessed by using the Egger test. No
evidence of publication bias was found for the studies included for assessing crude endocrine remission rate (p =
0.783) and new hypopituitarism rate (p = 0.222). However,
publication bias was evident for studies included for assessing crude tumor control rate (p = 0.021). Funnel plots
for publication bias are shown in Supplementary Fig. 5.
Supplementary Fig. 6 shows meta-regression plots for
association of mean margin dose with crude endocrine
remission rate and any new hypopituitarism rate. Metaregression analysis did not show a statistically significant
association of mean margin dose with crude endocrine
remission rate (p = 0.699) or mean margin dose with any
new hypopituitarism rate (p = 0.986).
J Neurosurg September 3, 2021
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FIG. 4. Forest plot for any new hypopituitarism rate for acromegaly. Squares indicate the proportions from individual studies and
horizontal lines indicate the 95% CI. The size of the data marker corresponds to the relative weight assigned in the pooled analysis
using the random effects model. The diamond indicates the pooled proportion with 95% CI.

Discussion

SRS is widely used in the management of PAs, both
nonsecretory and secretory. An ISRS-performed systematic review of the literature and consensus guidelines for
nonfunctioning adenomas (NFAs) of the pituitary have
recently been published.48 Whereas the goal of treatment
for NFAs is limited to tumor growth control, there is an
additional challenge for secretory adenomas, namely control of the associated hypersecretory syndrome. For this
systematic review, we selected 45 studies that reported the
outcomes of SRS for patients with secretory PA. There are
no prospective studies that have addressed this topic, to our
knowledge, and most papers are single-center retrospective
cohort studies and thus are evidence level IV studies. Nevertheless, there are still significant findings to guide patient
management and formulate recommendations (Table 1).
Tumor Growth Control
SRS has been mostly used in an adjuvant or recurrent
6

setting after prior tumor resection. All tumor types seem
to demonstrate excellent crude local tumor control after
SRS. Based on our meta-analysis, tumor control at last
follow-up can be expected in 97% of acromegaly patients,
92% of Cushing’s disease patients, and 93% of prolactinoma patients. These rates are similar to those reported in
NFA patients.48 However, there are a number of limitations
that need to be taken into consideration when interpreting these results. First, most studies reported only crude
control rates, and not actuarial time-dependent control
estimates. Long-term follow-up could reveal late tumor
regrowth, thus lowering control rates. In addition, the majority of investigators did not differentiate between actual tumor regression or stability in tumor size after SRS.
While this might not make a difference from a strictly
neuro-oncological point of view, this distinction remains
important and should be reported in future studies to better assess if tumor size variation after SRS has any impact
on endocrine outcome. Finally, none of the investigators
reported using volumetric evaluation for assessment of tu-
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FIG. 5. Forest plot for crude tumor control rate, crude endocrine remission rate, and any new hypopituitarism rate for Cushing’s disease. Squares
indicate the proportions from individual studies and horizontal lines indicate the 95% CI. The size of the data marker corresponds to the relative weight
assigned in the pooled analysis using the random effects model. The diamond indicates the pooled proportion with 95% CI. A: Forest plot for crude
tumor control rate. B: Forest plot meta-analysis for crude endocrine remission rate. C: Forest plot for any new hypopituitarism rate.
J Neurosurg September 3, 2021
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FIG. 6. Forest plot for crude tumor control rate, crude endocrine remission rate, and any new hypopituitarism rate for prolactinoma. Squares indicate the
proportions from individual studies and horizontal lines indicate the 95% CI. The size of the data marker corresponds to the relative weight assigned in
the pooled analysis using the random effects model. The diamond indicates the pooled proportion with 95% CI. A: Forest plot for crude tumor control
rate. B: Forest plot meta-analysis for crude endocrine remission rate. C: Forest plot for any new hypopituitarism rate.
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TABLE 1. Recommendations for the use of SRS as part of the management of secretory PAs
Indications for SRS
Effective option to control growth of GH-, ACTH-, & PRL-secreting residual or recurrent PAs after prior surgical resection but offers lower rate of
endocrine improvement or remission.
Could be used as primary therapy for GH- & ACTH-secreting PAs in patients deemed medically unfit for surgical resection.
Could be used as alternative to surgical resection for PRL-secreting PAs unresponsive to dopaminergic agonists.
Prescription dose
No minimal margin dose shown to definitively lead to better endocrine cure rates. Provided dose constraints safely protect surrounding structures
at risk (optic pathways, brainstem); higher margin doses can be used, although added therapeutic benefits in terms of remission remain not fully
defined.
SRS & use of antisecretory drugs
Withdrawal of antisecretory medications preferred, typically for 4–12 wks prior to radiosurgery, if safely possible considering endocrinologic status
of patient. Timing of temporary cessation of antisecretory medications & their reinstatement should be based on the particular agent pharmacology
& patient’s ability to tolerate brief withdrawal of medical management.
Endocrine remission & tumor response criteria
Investigators should report outcomes using most recently accepted consensus criteria for response, from perspectives of tumor volume & endocrine function.

mor size. Future studies should use 3D volumetric evaluations to report change in tumor dimensions after SRS,
ideally using standardized criteria such as RECIST (Response Evaluation Criteria in Solid Tumours).
Endocrine Remission After SRS
The clinical presentation of secretory PA is most often
related to the associated endocrinopathy rather than the
compression of adjacent neural structures, and thus endocrine control is usually the main goal of management.
Our meta-analysis confirms that SRS is more effective
to control tumor growth than provide endocrine remission. Crude estimates for endocrine remission were 44%
for acromegaly, 48% for Cushing’s disease, and 28% for
prolactinomas. These data must be interpreted with caution. First, most studies report crude endocrine remission
rates at last follow-up, and very few report actuarial rates
at different intervals. The biological effect of SRS on hormonal hypersecretion is believed to act over time. Therefore, crude rates might underestimate the true proportion
of patients who will achieve remission after some latency
period. For acromegaly, Pollock et al. reported cure rates
of 11% at 2 years and 60% at 5 years after SRS.14 Similarly,
Franzin et al. reported rates of 30.7%, 56.9%, and 80.4%
after 3, 5, and 10 years, respectively.7 Lee et al. reported
cure in 31.7% after 2 years, increasing to 64.5%, 73.4%,
and 82.6% at 4, 6, and 8 years, respectively.5 Similar results were reported by Sheehan et al. in Cushing’s disease
patients, with cure in 34% at 1 year, 54% at 2 years, 72%
at 3 years, and 78% at 5 years after SRS.34 In addition, the
analyzed literature spans a 20-year interval, during which
there have been changes in the criteria used to define endocrine remission. As recommended by most endocrinology
societies, those criteria have become more refined in the
recent years. The Cortina consensus defined acromegaly
remission as a random GH level less than 1 ng/ml or nadir
GH after an OGTT less than 0.4 ng/ml and normalization
of age- and sex-adjusted IGF-1 levels.49 The more recent
acromegaly consensus conference dropped the random GH

level requirement and only kept the other two criteria (nadir GH after OGTT and normalization of IGF-1 levels).31
In this systematic review, only one of the selected studies
used the more recent criteria to assess patients after SRS.
In a series of 52 patients, Iwata et al.25 reported a crude
cure rate of only 17%. Using the older Cortina consensus
criteria, Sala et al.24 achieved a cure in 41% of 22 patients
included in their study. In comparison, by using GH levels
less than 2.5 ng/ml, Franzin et al.7 reported a cure rate of
60.7% and Yan et al.27 obtained a cure in 68.2% of patients.
The same variability in endocrine cure definition is seen in
Cushing’s disease and prolactinoma studies. For Cushing’s
disease, normal 24-hour urinary free cortisol has been the
most frequent criterion used. Alternatively, many authors
used serum cortisol or ACTH levels, alone or in combination with urinary levels. For prolactinomas, most study
investigators used normal PRL levels to define remission
without specifying normal value ranges. Using more severe criteria will negatively impact cure rates, yet this is
something that needs to be systematized moving forward.
Hypopituitarism After SRS
Among all included studies for all 3 secretory subtypes,
new-onset or worsening of preexisting hypopituitarism
was reported in 0%–50% of treated patients. Our metaanalysis failed to identify any significant factor associated with an increase in new hormone deficiency risk. No
article included in the meta-analysis has demonstrated a
correlation between endocrine remission and hypopituitarism, and we also could not find any such relation with the
pooled data. We also could not find any relation between
the margin dose and the risk of hypopituitarism. However,
this lack of association might be more related to the poor
quality of the included studies than a real lack of effect. As
is the case for endocrine remission reporting, there is wide
heterogenicity in the way studies report hypopituitarism
(clinical vs biochemical confirmation, lack of pre-SRS hypopituitarism mention, lack of individual axis evaluation).
In addition, because most studies only report crude hypoJ Neurosurg September 3, 2021
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pituitarism rates, this likely leads to an underestimation of
the risk, as the rate of new hormone deficiency is likely to
increase over time.
Impact of the Prescription Dose
PAs are usually benign in histology, and as such, single-fraction radiation doses of between 12 and 16 Gy have
been demonstrated to provide durable control of tumor
growth in NFA.48 This may also apply to hormone-secreting tumors, as crude tumor control rates between 83% and
100% have been reported across all 3 different studied
subtypes, using median margin doses as low as 13–14 Gy
in some studies.13,28 However, it has been widely believed
that the doses required to stop the cellular mechanisms
associated with hormonal hypersecretion are much higher than those required to control cellular division, and as
such most authors have tried to deliver margin doses up to
the range of 30–40 Gy, usually limited by the constraints
of tumor volume and the proximity of optic apparatus.
Despite this, only 2 of the selected studies actually found
margin dose to be relevant for outcomes. In a study of
68 acromegalic patients, Zhang et al. found better tumor
control and resolution of hypertension and hyperglycemia if margin doses were higher than 30 Gy.21 Pan et al.
reported improved chances of hyperprolactinemia resolution with margin doses of 30 Gy or more in 128 prolactinoma patients.45 Our meta-regression analysis failed
to demonstrate a relation between mean margin dose and
crude endocrine remission rates for any of the 3 studies
of tumor subtypes. However, this might only represent the
fact that most authors have inherently used a dose selection threshold that is higher than the required one to produce an effect on hormone hypersecretion and might not
be truly indicative of a lack of effect. In addition, regarding dose selection, the concept of a biologically effective
dose (BED) might be more important for outcomes than
the absolute dose. In a recent study of the Mayo Clinic
acromegaly series (not included in this meta-analysis),
BED remained the only factor correlated with endocrine
remission on multivariate analysis.50 Regarding morbidity, we could not find any link between margin dose and
the risk of pituitary function worsening among all tumor
types, and the ophthalmological and neurological morbidity was low in the majority of studies, despite the high
margin dose used. None of the included studies reported
that increasing margin dose led to higher risk of visual
or neurological morbidity. Lee et al. used a dose of 25
Gy in 136 acromegalic patients, 5 with only 2.9% suffering
from new visual field deficits and 0.7% new oculomotor
palsy. Despite using 35 Gy, Jezková et al. did not report
visual or neurological morbidity in 96 patients with acromegaly.16 Visual deterioration was reported in 11.1% of 71
patients in Kobayashi’s acromegaly series, despite using
a lower mean margin dose of 18.9 Gy.12 Based upon the
available literature, if neuroanatomical dose constraints
allow, higher margin doses could be utilized, although the
added therapeutic benefit in terms of remission remains
not fully defined.
Impact of Antisecretory Medication
The use of antisecretory drugs at the time of SRS is
10

considered to negatively affect endocrine remission. For
acromegaly, only the study by Pollock et al. confirmed
this fact, with an HR of 4.2 of achieving remission when
patients were off compared to on medication at SRS.14
Alternatively, 3 studies did not find medication intake to
impact cure rates.5,15,17 It is worth noting that for the most
recent acromegaly studies, suppressive medications were
stopped for 1 to 4 months before SRS in all patients, making it difficult to confirm whether this is of importance
or not.3,4,24,26,27 For prolactinomas, no study found a link
between dopamine agonist intake and cure. Cohen-Inbar
et al. reported that the use of a dopamine agonist at the
time of SRS decreased cure rates from 50% in patients off
medication to 38.1%, but the difference failed to reach statistical significance.40 Two other studies mentioned no difference in endocrine remission based on medication intake
at SRS.41,43 The impact of antisecretory medication is even
less clear for Cushing’s disease. The most common drug
to control corticoid hypersecretion, ketoconazole, acts by
decreasing peripheral cortisol synthesis at the adrenal level, although it might also reduce ACTH release from the
anterior pituitary, as suggested by a preclinical study.51 In
the study by Sheehan et al., patients who were off ketoconazole at SRS had faster time to endocrine remission than
patients on medication, but the overall endocrine remission
rates were no different.34 Conversely, Castinetti et al. found
statistically significantly better cure rates in patients off
ketoconazole at the time of SRS (48% vs 20%).36 Taking
all into consideration, it appears reasonable to recommend
withholding antisecretory medication for 4 to 12 weeks
(depending on the individual drug’s pharmacokinetic profile) before SRS in patients in whom the endocrine status
is stable and temporary drug cessation is not expected to
cause any harmful deterioration.
Timing of SRS in the Multimodality Management of
Secretory PAs
The management of secretory PAs frequently necessitates a combination of different modalities. SRS is usually viewed as a second or third-line option, after surgical or medical management. This is reflected in our
meta-analysis, whereas the majority of included studies
of acromegaly or Cushing’s disease reported patients
treated after surgical resection. Our results might not be
applicable to patients who did not have prior resection.
As such, we believe that patients who are deemed medically fit should be offered surgery as first-line management if possible. However, there was more heterogenicity
in the prior management of patients who were included in
our prolactinoma analyses, reflecting the fact that prolactinomas are exquisitely responsive to drug therapy, and
surgery is rarely required for those patients. In addition,
medically refractory prolactinomas tend to be more locally invasive, and surgery is generally deemed less likely
to provide endocrine cure. In the study by Pan et al., only
2.3% of patients had prior surgical resection.45 Similarly,
Jezková et al. reported resection in only 28.6% of patients
before SRS.43 SRS seems to be used more liberally as
second-line therapy and might be more appropriately recommended in this setting for prolactinomas than GH- or
ACTH-secreting tumors.
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Single-Fraction Versus Hypofractionated SRS
In this meta-analysis, we deliberately chose to exclude
fractionated stereotactic radiation therapy (SRT) studies
and focused on SRS studies. Since the literature is already
heterogeneous with respect to single-fraction SRS, the inclusion of the limited number of fractionated SRT studies
would only add confounding factors to our study. Taking
into account the accepted ISRS-endorsed definition of
SRS, 2 hypofractionated SRS acromegaly studies that otherwise satisfied all inclusion criteria were included in the
analysis.24,25 However, the results of those studies cannot
be interpreted separately from the more prevalent singlefraction studies, so extrapolations of equivalency must be
made with caution.

Conclusions

SRS offers effective tumor control of hormone-producing PAs in the majority of patients but a lower rate of endocrine improvement or remission. However, the quality of
evidence that can be extracted from the existing literature
on SRS for secretory PAs is low, with most studies being single-center retrospective studies in design. Limited
practice recommendations can be formulated based on
the evidence, and those recommendations are applicable
only to the secretory subtypes included in this study (GH-,
ACTH-, and PRL-secreting tumors) and should not be extrapolated to other histological subtypes.
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Disclaimer

These guidelines should not be considered inclusive of all methods of care or exclusive of other methods or care reasonably
directed to obtain similar results. The physician must make the
ultimate judgment depending on characteristics and circumstances of individual patients. Adherence to this guideline will
not ensure successful treatment in every situation. The authors
of this guideline and the International Society of Stereotactic
Radiosurgery assume no liability for the information, conclusions,
and recommendations contained in this report.
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